Abstract
The incidence of HIV-associated dementia has been greatly reduced in the era of highly active antiretroviral therapy (HAART); however milder forms of cognitive impairment persist. It remains uncertain whether HAART regimens with a high degree of central nervous system penetration effectiveness (CPE) exert beneficial neurological outcomes in HIV-infected (HIV+) individuals on stable treatment. Sixty-four HIV-infected adults on HAART were assigned a CPE score using a published ranking system and divided into high (≥7; n = 35) and low (<7; n = 29) CPE groups. All participants completed neuropsychological testing in addition to structural neuroimaging. Neuropsychological tests included measures known to be sensitive to HIV with values converted into standardized scores (NPZ-4) based on published normative scores. A semi-automated methodology was utilized to assess brain volumetrics within cortical (grey and white matter) and subcortical (thalamus, caudate, putamen) regions of interest. Analyses assessed NPZ-4 and brain volumetric differences between HIV+ individuals with high and low CPE scores. No significant differences in brain integrity were observed between the two groups. Long-term HAART regimens with a high degree of CPE were not associated with significantly improved neuropsychological or neuroimaging outcomes in HIV+ adults. Results suggest that alternate mechanisms may potentially contribute to better neurological outcomes in the era of HAART.
Similar content being viewed by others
References
Ances BM, Ortega M, Vaida F, Heaps J, Paul R (2012) Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 59(5):469
Au R, Seshadri S, Wolf PA, Elias MF, Elias PK, Sullivan L, D’Agostino RB (2004) New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res 30(4):333–358
Benedict RH, Schretlen D, Groninger L, Brandt J (1998) Hopkins verbal learning test–revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12(1):43–55
Caniglia EC, Cain LE, JusticeA, Tate J, Logan R, Sabin C, Hernán MA (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 10–1212
Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Fauci AS (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (London, England) 24(18):2803
Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, Ellis RJ (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73(5):342–348
Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis: I. Segmentation and surface reconstruction. Neuroimage 9(2):179–194
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31(3):968–980
Eisfeld C, Reichelt D, Evers S, Husstedt I (2013) CSF penetration by antiretroviral drugs. CNS Drugs 27(1):31–55
Fischl B, Sereno MI, Dale AM (1999) Cortical surface-based analysis: II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 9(2):195–207
Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, Dale AM (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex 14(1):11–22
Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK (1999) Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 6(2):147–178
Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, CHARTER Group (2009) White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol 15(2):187–195
Goodglass H, Kaplan E (1972) The assessment of aphasia and related disorders. Lea & Febiger, Philadelphia, pp 1–80
Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Heaton RK (2014) Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 10–1212
Heaps JM, Joska J, Hoare J, Ortega M, Agrawal A, Seedat S, Paul R (2012) Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol 18(3):151–156
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 75(23):2087–2096
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3–16
Heaton RK, Franklin DR, Deutsch R, Letendre SL, Ellis RJ, Casaletto K, Mintz L (2014) Neurocognitive change in the era of HIV combination antiretroviral therapy: a longitudinal CHARTER study. Clin Infect Dis ciu862
Hua X, Boyle CP, Harezlak J, Tate DF, Yiannoutsos CT, Cohen R, Thompson PM (2013) Disrupted cerebral metabolite levels and lower nadir CD4+ counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin 3:132–142
Kahouadji Y, Dumurgier J, Sellier P, Lapalus P, Delcey V, Bergmann JF, Paquet C (2013) Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med 14(5):311–315
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70
Letendre SL, Ellis RJ, Everall I, Ances B, Bharti A, McCutchan JA (2009) Neurologic complications of HIV disease and their treatment. Top HIV Med Publ Int AIDS Soc USA 17(2):46
Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, AIDS Clinical Trials Group 736 Study Team (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (London, England) 23(11):1359
McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Saah A (1993) Dementia in AIDS patients incidence and risk factors. Neurology 43(11):2245–2245
McManus H, Li PCK, Nolan D, Bloch M, Kiertiburanakul S, Choi JY, Wright E (2011) Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV‐infected adults? HIV Med 12(10):610–619
Moretti S, Alesse E, Marcellini S, Marzio LD, Zazzeroni F, Parroni R, De Simone C (1999) Combined antiviral therapy reduces Hiv-1 plasma load and improves CD4 counts but does not intere with ongoing lymphocyte apoptosis. Immunopharmacol Immunotoxicol 21(4):645–665
Norman MA, Moore DJ, Taylor M, Franklin D Jr, Cysique L, Ake C, HNRC Group (2011) Demographically corrected norms for African Americans and Caucasians on the hopkins verbal learning test–revised, brief visuospatial memory test–revised, stroop color and word test, and wisconsin card sorting test 64-card version. J Clin Exp Neuropsychol 33(7):793–804
Ortega M, Heaps JM, Joska J, Vaida F, Seedat S, Stein DJ, Ances BM (2013) HIV clades B and C are associated with reduced brain volumetrics. J Neurovirol 19(5):479–487
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338(13):853–860
Reitan RM, Davison LA (1974) Clinical neuropsychology: current status and applications. Hemisphere, New York
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21(14):1915–1921
Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, HNRC Group (2005) Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 11(4):356–364
Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Valcour VG (2012) Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 17(7):1233
Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (London, England) 25(3):357
Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Antinori A (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. JAIDS J Acquir Immune Defic Syndr 52(1):56–63
Valcour VG (2012) HIV, aging, and cognition: emerging issues. Top Antivir Med 21(3):119–123
Zatz LM, Jernigan TL (1983) The ventricular-brain ratio on computed tomography scans: validity and proper use. Psychiatry Res 8(3):207–214
Acknowledgments
The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.
Sources of Funding
Financial Support: Supported by the National Institute of Nursing Research (R01NR012907, R01NR012657, and R01NR014449 to B.M.A.); Grossman Chancellor’s Fellowship (M.O.); National Science Foundation IGERT (0548890 to M.O.), and the National Institute of Aging (R01 NS052420) (R.H.P.). Research was conducted and supported by the Washington University Institute of Clinical and Translational Sciences (UL1 TR000448 from the National Center for Advancing Translational Sciences (NCATS)).
Conflicts of Interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baker, L.M., Paul, R.H., Heaps-Woodruff, J.M. et al. The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals. J Neuroimmune Pharmacol 10, 487–492 (2015). https://doi.org/10.1007/s11481-015-9610-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-015-9610-4